Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly and Company

Roche gets European approval for Alzheimer’s diagnosis blood test

Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnostic methods.

Euronews

Eli Lilly and Co Reportedly Close to $2 Billion Acquisition of Kelonia Therapeutics

Eli Lilly is reportedly nearing a $2 billion deal to acquire Kelonia Therapeutics, aiming to expand its cancer treatment portfolio with next-generation therapies.

International Business Times

Beyond the Slopes: Mikaela Shiffrin’s Mission to Help Educate Families Facing Early Symptomatic Alzheimer’s Disease

Mikaela was compensated for her time by Eli Lilly and Company. The Most Decorated Skier of Our Time Mikaela Shiffrin knows what it means to chase down a challen

Sports Illustrated

From analysis to the latest developments in health,
read the most diverse news in one place.

New fleet of weight loss drugs are more effective than the current popular obesity medications at trial

One in eight Americans are taking a GLP-1 drug, a recent poll found

The Independent UK

As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?

Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.

Barchart

This next-gen weight-loss drug offers a new hope — and a bonus Ozempic and Wegovy don’t have

The once-weekly shot may be a tempting alternative to popular GLP-1 class drugs like Ozempic and Wegovy

The Independent UK

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times

Read news from The Economist, FT, and more,
with one subscription

3 Dividend Stocks Beating the Market Chaos While Analysts Rate Them a "Strong Buy"

While investors are fleeing the market chaos, these three analyst-backed dividend stocks are quietly surging, with financials too strong to ignore.

Barchart

Are Wall Street Analysts Bullish on Eli Lilly Stock?

Despite lagging behind the broader market over the past year, Eli Lilly continues to enjoy a highly bullish outlook from Wall Street analysts, who remain confident in the company’s long-term growth potential.

Barchart

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

StockNews.com

Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns?

The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.

StockNews.com

3 Top Healthcare Stocks to Buy for Growth and Dividends

Investors seeking growth and dividend income in the healthcare sector may want to consider Eli Lilly, Gilead Sciences, and Amgen, which have delivered impressive returns and boast strong pipelines and strategic moves.

Barchart

3 Healthcare Stocks to Watch as the Aging Population Drives Demand

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

StockNews.com

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

Fortune

Alphabet’s next CFO Anat Ashkenazi ‘fills a void’ for the company at key time during AI Revolution, says top analyst

Ashkenazi is a 23-year veteran of Eli Lilly and Company.

Fortune

Google and Alphabet’s new CFO is Eli Lilly’s Anat Ashkenazi

Ashkenazi will have the task of investing in the company’s next wave of growth in the AI era.

StockNews.com

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

StockNews.com

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

StockNews.com

Top 4 Pharma Picks for January 2024 Growth

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

Fortune

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

StockNews.com

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

StockNews.com

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

3 Rising Pharma Stocks to Consider Buying Now

The pharmaceutical sector is transforming due to the swift uptake of digital solutions and worldwide spending growth. Hence, fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Astellas Pharma (ALPMY), and Eli Lilly (LLY) might be solid buys now. Read more….

1 2 3

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.